Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer

被引:12
|
作者
Gogineni, Emile [1 ]
Rana, Zaker [1 ]
Soberman, Danielle [1 ]
Sidiqi, Baho [1 ]
D'Andrea, Vincent [1 ]
Lee, Lucille [1 ]
Potters, Louis [1 ]
Parashar, Bhupesh [1 ]
机构
[1] Donald & Barbara Zucker Sch Med Hofstra Northwell, Acad Dept Radiat Med, Hempstead, NY 11549 USA
关键词
EXTERNAL-BEAM RADIOTHERAPY; TRIAL; MONOTHERAPY; SPACER;
D O I
10.1016/j.ijrobp.2020.11.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Low-dose-rate (LDR) brachytherapy and stereotactic body radiation therapy (SBRT) have both shown acceptable outcomes in the treatment of low- and intermediate-risk prostate cancer. Minimal data have been published directly comparing rates of biochemical control and toxicity with these 2 modalities. We hypothesize that LDR and SBRT will provide similar rates of biochemical control. Methods and Materials: All low- and intermediate-risk patients with prostate cancer treated definitively with SBRT or LDR between 2010 and 2018 were captured. Phoenix definition was used for biochemical failure. Independent t tests were used to compare baseline characteristics, and repeated measure analysis of variance test was used to compare American Urologic Association (AUA) and the Expanded Prostate Cancer Index Composite (EPIC) scores between treatment arms over time. Biochemical control was estimated using the Kaplan-Meier method. Differences in acute and late toxicity were assessed via Pearson chi(2). Results: In the study, 219 and 118 patients were treated with LDR and SBRT. Median follow-up was 4.3 years (interquartile range, 3.1-6.1). All patients treated with LDR received 125.0 Gy in a single fraction. SBRT consisted of 42.5 Gy in 5 fractions. Five-year biochemical control for LDR versus SBRT was 91.6% versus 97.6% (P =.108). LDR patients had a larger increase in mean AUA scores at 1 month (17.2 vs 10.3, P <.001) and 3 months posttreatment (14.0 vs 9.7, P <.001), and in mean EPIC scores at 1 month (15.7 vs 13.8, P <.001). There was no significant difference between LDR and SBRT in late grade 3 genitourinary toxicity (0.9% vs 2.5%, P =.238); however, LDR had lower rates of late grade 3 gastrointestinal toxicity (0.0% vs 2.5%, P =.018). Conclusions: Our data show similar biochemical control and genitourinary toxicity rates at 5 years for both SBRT and LDR, with slightly higher gastrointestinal toxicity with SBRT and higher AUA and EPIC scores with LDR. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:1232 / 1242
页数:11
相关论文
共 50 条
  • [1] Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer
    Gestaut, Matthew M.
    Cai, Wendi
    Vyas, Shilpa
    Patel, Belur J.
    Hasan, Salman A.
    MunozMaldonado, Yolanda
    Deb, Niloyjyoti
    Swanson, Gregory
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 101 - 107
  • [2] Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
    Kunogi, Hiroaki
    Wakumoto, Yoshiaki
    Kawamoto, Terufumi
    Oshima, Masaki
    Horie, Shigeo
    Sasai, Keisuke
    [J]. JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (06) : 554 - 561
  • [3] RADIATION DOSE PREDICTS FOR BIOCHEMICAL CONTROL IN INTERMEDIATE-RISK PROSTATE CANCER PATIENTS TREATED WITH LOW-DOSE-RATE BRACHYTHERAPY
    Ho, Alice Y.
    Burri, Ryan J.
    Cesaretti, Jamie A.
    Stone, Nelson N.
    Stock, Richard G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01): : 16 - 22
  • [4] Prospective Evaluation of Stereotactic Body Radiation Therapy for Low- and Intermediate-risk Prostate Cancer: Emulating High-dose-rate Brachytherapy Dose Distribution
    Fuller, D. B.
    Mardirossian, G.
    Wong, D.
    Morris, D.
    Underhil, K.
    Medbery, C.
    Peddada, A.
    McKellar, H.
    Gray, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S149 - S149
  • [5] A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men
    Li, Youquan
    Ngai, Thomas Chan Kong
    Zhou, Siqin
    Hwong, Jerome Yap Haw
    Ping, Eric Pang Pei
    Li Kuan, Ashley Ong
    Chek, Michael Wang Lian
    Kiang, Melvin Chua Lee
    Looi, Wen Shen
    Nei, Wen Long
    Chua, Eu Tiong
    On, Weber Lau Kam
    Kiat, Terence Tan Wee
    Peng, John Yuen Shyi
    Loong, Jeffrey Tuan Kit
    [J]. ACTA ONCOLOGICA, 2021, 60 (10) : 1291 - 1295
  • [6] Comparing the Cost-Effectiveness of Low-Dose-Rate Brachytherapy, High-Dose-Rate Brachytherapy, and Hypofactionated Intensity Modulated Radiation Therapy for the Treatment of Low-/Intermediate-Risk Prostate Cancer
    Lanni, T.
    Krauss, D.
    Marvin, K. S.
    Gustafson, G.
    Ye, H.
    Chen, P.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S587 - S588
  • [7] Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
    Jeong, Bae-Kwon
    Jeong, Hojin
    Ha, In Bong
    Choi, Hoon Sik
    Kam, Sung Chul
    Hwa, Jeong Seok
    Hyun, Jae Seog
    Chung, Ky Hyun
    Choi, See Min
    Kang, Ki Mun
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (06) : 710 - 715
  • [8] Intermediate-Risk Prostate Cancer Treated With Definitive Low-dose-rate Brachytherapy
    Ester, E. C.
    Wang, X.
    Vernon, M. R.
    Olson, N. J.
    Shanley, R. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S405 - S405
  • [9] Definitions of "Cure" After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
    Boehle, Andreas
    Zywietz, Dorothea
    Robrahn-Nitschke, Irina
    Koenig, Inke R.
    Lusch, Achim
    [J]. ADVANCES IN RADIATION ONCOLOGY, 2023, 8 (02)
  • [10] Dose-Escalated Stereotactic Body Radiation Improves Outcomes in Patients with Low- and Intermediate-Risk Prostate Cancer
    Cox, B. W.
    Rana, Z.
    Lee, L.
    Potters, L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E105 - E105